Novel pharmacotherapies for cardiac amyloidosis.

ABSTRACT: Amyloidosis refers to a range of protein misfolding disorders that can cause organ dysfunction through progressive fibril deposition. Cardiac involvement often leads to significant morbidity and mortality and increasingly has been recognized as an important cause of heart failure. The two main forms of cardiac amyloidosis, light chain (AL) and transthyretin (ATTR) amyloidosis, have distinct mechanisms of pathogenesis. Recent insights have led to the development of novel pharmacotherapies with the potential to significantly impact each disease. This review will summarize the preclinical and clinical data for these emerging treatments for AL and ATTR amyloidosis.

SUBMITTER: Alexander KM 

PROVIDER: S-EPMC5832446 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature